JP2015510393A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510393A5
JP2015510393A5 JP2014553578A JP2014553578A JP2015510393A5 JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5 JP 2014553578 A JP2014553578 A JP 2014553578A JP 2014553578 A JP2014553578 A JP 2014553578A JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
peptide according
agent
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553578A
Other languages
English (en)
Japanese (ja)
Other versions
JP6249447B2 (ja
JP2015510393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/000045 external-priority patent/WO2013110120A1/en
Publication of JP2015510393A publication Critical patent/JP2015510393A/ja
Publication of JP2015510393A5 publication Critical patent/JP2015510393A5/ja
Application granted granted Critical
Publication of JP6249447B2 publication Critical patent/JP6249447B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553578A 2012-01-24 2013-01-24 癌治療用ペプチド剤 Expired - Fee Related JP6249447B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012900259A AU2012900259A0 (en) 2012-01-24 Agents for use in cancer therapy
AU2012900259 2012-01-24
AU2012904368 2012-10-06
AU2012904368A AU2012904368A0 (en) 2012-10-06 Anti-cancer peptides
PCT/AU2013/000045 WO2013110120A1 (en) 2012-01-24 2013-01-24 Peptide agents for cancer therapy

Publications (3)

Publication Number Publication Date
JP2015510393A JP2015510393A (ja) 2015-04-09
JP2015510393A5 true JP2015510393A5 (enExample) 2016-03-17
JP6249447B2 JP6249447B2 (ja) 2017-12-20

Family

ID=48872819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553578A Expired - Fee Related JP6249447B2 (ja) 2012-01-24 2013-01-24 癌治療用ペプチド剤

Country Status (7)

Country Link
US (1) US9403877B2 (enExample)
EP (1) EP2807180B1 (enExample)
JP (1) JP6249447B2 (enExample)
CN (1) CN104271590B (enExample)
AU (1) AU2013202137B2 (enExample)
CA (1) CA2862485C (enExample)
WO (1) WO2013110120A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
CN105294839A (zh) * 2015-10-28 2016-02-03 上海大学 对新生血管形成有阻断功能的多肽化合物及其应用
CN106146620A (zh) * 2016-07-09 2016-11-23 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN106167513A (zh) * 2016-07-09 2016-11-30 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN106084012A (zh) * 2016-07-09 2016-11-09 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN105936643A (zh) * 2016-07-09 2016-09-14 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN105936642A (zh) * 2016-07-09 2016-09-14 青岛大学 具有抑制癌细胞生长活性的肽及其应用
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
KR20210021984A (ko) * 2018-05-15 2021-03-02 인터크 펩타이드 테라퓨틱스 리미티드 펩타이드 활성화 제제
US12134663B2 (en) * 2018-05-15 2024-11-05 Interk Peptide Therapeutics Limited Cationic peptides for activating Lck
KR20210097729A (ko) * 2018-11-30 2021-08-09 인터크 펩타이드 테라퓨틱스 리미티드 피부 병태를 개선하기 위한 폴리펩타이드 및 방법
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
CN112646018B (zh) * 2021-01-25 2023-04-28 井冈山大学 一种抑制肿瘤细胞增殖和转移的生物活性肽及其应用
CN117979985A (zh) * 2021-08-20 2024-05-03 英特肽治疗有限公司 用于治疗包括与癌症和癌症疗法相关的自身免疫在内的自身免疫的组合物和方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
MXPA02012198A (es) 2000-06-09 2004-08-19 Teni Boulikas Encapsulacion de polinucleotidos y drogas en liposomas objetivos.
US6696546B1 (en) * 2000-11-06 2004-02-24 The Trustees Of Columbia University In The City Of New York Peptide that kills growing but not stationary cells
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
WO2002053726A2 (en) * 2001-01-02 2002-07-11 Hybrigenics Protein-protein interactions in adipocyte cells
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
PT2302063T (pt) 2001-10-15 2016-07-28 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
CN101905024A (zh) 2001-11-16 2010-12-08 杰南技术公司 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
AU2004281077B2 (en) * 2003-10-17 2010-12-02 Inter-K Pty Limited Methods and agents for the treatment of cancer
US7183257B2 (en) * 2004-04-14 2007-02-27 The Brigham And Women's Hospital, Inc. Use of RPL41 to treat infections and inhibit cancer
US20060194319A1 (en) 2004-09-02 2006-08-31 Webb Carol F Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
US7429481B2 (en) 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US7912214B2 (en) 2007-07-20 2011-03-22 Amadeus S.A.S. Method and system for generating and controlling the distribution and use of personal promotion codes by targeted customers
WO2009103127A1 (en) * 2008-02-22 2009-08-27 Inter-K Pty Limited Therapeutic peptides
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
WO2010039778A2 (en) * 2008-09-30 2010-04-08 Zirus, Inc. Mammalian genes involved in infection
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害

Similar Documents

Publication Publication Date Title
JP2015510393A5 (enExample)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
ES2869901T3 (es) Agentes inmunosupresores y su uso en terapia
JP2015518818A5 (enExample)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2011528896A5 (enExample)
JP2012041342A5 (enExample)
JP2017537611A5 (enExample)
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
JP2015517488A5 (enExample)
JP2012176978A5 (enExample)
JP2011528895A5 (enExample)
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
JP2010506826A5 (enExample)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
JP2017532343A5 (enExample)
JP2014529399A5 (enExample)
IN2014DN09963A (enExample)
JP2019533722A5 (enExample)
JP2011528897A5 (enExample)
WO2016145234A3 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
NZ708990A (en) Method for activating helper t cell
BR112013006088A2 (pt) Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada"
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos